logo

For the Inventor, By the Inventor

Gyeonggi-do, South Korea

Sk Biopharmaceuticals Co., Ltd.


USPTO Granted Patents = 109



Trademarks = 13

Forward Citations = 923

Loading Chart...
Loading Chart...

254 inventors (with patents filed for the assignee):

goldMedal Moise A Khayrallah (15 out of 16 patents)

silverMedal Gary Bream (15 out of 16 patents)

bronzeMedal Stephen E Butts (15 out of 17 patents)

4.  Susan Marie Melnick (14 out of 14 patents)

5.  Young Koo Jang (11 out of 11 patents)

6.  Chan Mi Joung (11 out of 15 patents)

7.  Hye Won Shin (10 out of 10 patents)

8.  Ji Won Lee (9 out of 43 patents)

9.  Cheol Young Maeng (9 out of 9 patents)

10.  Yu-Jin Shin (9 out of 9 patents)

11.  Sung James Lee (9 out of 9 patents)

12.  Han Ju Yi (9 out of 9 patents)

13.  Jonathan Sporn (8 out of 8 patents)

14.  Ju Young Lee (8 out of 26 patents)

15.  Sun Gwan Hwang (8 out of 9 patents)


Core Competencies:
Carbamate Compounds
Bicyclic Compounds
Oxadiazole Derivatives
Imidazopyrimidine
Pharmaceutical Compositions
Sleep-Wake Disorders
Obesity Treatment
Cataplexy Treatment
Schizophrenia Mitigation
Visceral Pain Treatment
Attention-Deficit/Hyperactivity Disorder
Fibromyalgia Management

109 patents:

1. 12465591 - Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy (2025-11-11),
2. 12409164 - Orally disintegrated tablet comprising carbamate compound (2025-09-09),
3. 12384743 - Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof (2025-08-12),
4. 12331035 - Bicyclic compound and use thereof (2025-06-17),
5. 12226399 - Oral aqueous suspension formulation comprising carbamate compound (2025-02-18),
6. 12209059 - Treatment of sleep-wake disorders (2025-01-28),
7. 12201601 - Treatment for obesity (2025-01-21),
8. 12162821 - Treatment of cataplexy (2024-12-10),
9. 12145914 - Compound having oxadiazole and pharmaceutical composition containing the same (2024-11-19),
10. 12070448 - Use of carbamate compound for prevention, alleviation or treatment of status epilepticus (2024-08-27),
11. 12070447 - Parenteral liquid preparation comprising carbamate compound (2024-08-27),
12. 12037338 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2024-07-16),
13. 11753368 - Treatment of sleep-wake disorders (2023-09-12),
14. 11725001 - Bicyclic compound and use thereof (2023-08-15),
15. 11717509 - Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia (2023-08-08),
SK Biopharmaceuticals is a global pharmaceutical company specializing in the research and development of innovative therapies for central nervous system (CNS) disorders. With a commitment to improving patient outcomes, SK Biopharmaceuticals focuses on discovering and commercializing novel treatments for epilepsy and other CNS conditions. As a leader in the field, SK Biopharmaceuticals leverages its expertise and cutting-edge technologies to deliver superior medical solutions for patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

109 Patents

#13 in Gyeonggi-do

#167 in South Korea

#7,003 in the World

...
Gyeonggi-do, South Korea

Sk Biopharmaceuticals Co., Ltd.

Forward Citations = 923

254 inventors:

goldMedal Moise A Khayrallah (15 out of 16 patents)

silverMedal Gary Bream (15 out of 16 patents)

bronzeMedal Stephen E Butts (15 out of 17 patents)

4.  Susan Marie Melnick (14 out of 14 patents)

5.  Young Koo Jang (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com
Loading…